Global Biosimilars Market Size & Trends Report Segmented by Product (mAbs, Insulin, G-CSF, Erythropoietin, hGH, Interferons), Application (Oncology, Autoimmune, Diabetes, Blood Disorders, Infectious Diseases), Manufacturing Type (In-house, Contract) Forecast to 2030
The global biosimilars market is set to witness a CAGR of ~15% in the next 5 years. Impending patent expiry of blockbuster biologics, cost containment strategies by governments and payers, rising demand for affordable alternatives for costly biologics, strong regulatory support and clear guidelines, and increased physician and patient acceptance are some of the key factors driving the biosimilars market. To learn more about the research report, download a sample report.
Report Overview
Biosimilars are biologic medical products that are highly similar to an already approved original biologic (reference product), with no clinically meaningful differences in safety, purity, and effectiveness. The development of biosimilars is complex because, like all biologics, it involves use of living cells and complex manufacturing processes. Therefore, while biosimilars are similar to the reference biologic, they are not identical. The manufacturer must perform an extensive analytical, preclinical, and clinical evaluation to demonstrate similarity. Biosimilars are not just generic alternatives to expensive biologics; instead, they are a viable and reasonable cost alternative to the original biologic, particularly when the reference product's patent has expired. Biosimilars are widely used in the treatment and management of chronic and life-threatening diseases, such as cancer, diabetes, and autoimmune diseases. They help improve access to advanced therapies available globally for patients.
To learn more about this report, download the PDF brochure
Impending patent expiry of blockbuster biologics to drive market growth
The impending patent expiries of best-selling biologics is a key factor driving growth of the biosimilars market. A major opportunity for cost savings remains untapped, as many high-value biologics nearing the end of patent protection and exclusivity still lack biosimilar development, delaying broader market competition and affordability. These revenue-generating biologics will be losing exclusivity and allowing biosimilar manufacturers to introduce products at lower costs in the biopharmaceutical market. This leads to competitive pricing, increases the number of patients receiving access to biosimilars, and reduction in overall healthcare costs. With most top-selling biologics nearing, if not already passed, patent expiry, companies are investing into biosimilars to take benefit of this opportunity. Regulators have also promoted a favorable environment for biosimilars during this timeframe by updating their approval pathways, leading to an overall acceleration of biosimilar entry into the market when the patent expires.
Strategic partnerships and market consolidation – A key market trend
Partnerships and market consolidation is a key trend shaping this market as this to decrease development costs, share risks, and launch products in a timely manner. Partnerships involving global pharmaceutical companies and local firms, contract manufacturers/developers, and biotech firms allows them to combine their abilities which helps to gain advanced technology, knowledge of the regulatory pathway, and existing infrastructure network for distribution. For instance, in May 2025 Alvotech expanded its biosimilar partnership with Advanz Pharma and added 3 new biosimilar candidates. Similarly, in July 2024, Evotec SE extended its biosimilar strategic partnership with Sandoz. Furthermore, the mergers and acquisitions taking place in the biosimilar marketplace are facilitating consolidation in the competitive landscape, enabling companies to scale operations and diversify their portfolios. Thus, partnerships can expand their worldwide reach, streamline production processes and support commercialization in the competitive and regulated biosimilar sector.
To learn more about this report, download the PDF brochure
Competitive Landscape Analysis
The global biosimilars market is marked by the presence of established and emerging market players such as Sandoz Group AG, Pfizer Inc., Amgen Inc., Teva Pharmaceuticals, Inc., Biocon, Eli Lilly and Company, Celltrion Inc., Fresenius SE & Co. KGaA, Samsung Bioepis, and Dr. Reddy’s Laboratories Ltd.; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Report Scope
| Report Metric | Details |
| Base Year Considered | 2024 |
| Historical Data | 2023 - 2024 |
| Forecast Period | 2025 - 2030 |
| Growth Rate | ~15% |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | By Product, Application, Manufacturing Type |
| Regional Scope |
|
| Key Companies Mapped | Sandoz Group AG, Pfizer Inc., Amgen Inc., Teva Pharmaceuticals, Inc., Biocon, Eli Lilly and Company, Celltrion Inc., Fresenius SE & Co. KGaA, Samsung Bioepis, and Dr. Reddy’s Laboratories Ltd. among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Biosimilars Market Segmentation
This report by Medi-Tech Insights provides the size of the global biosimilars market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product, application, and manufacturing type.
Market Size & Forecast (2023-2030), By Product, USD Million
- Monoclonal Antibodies (mAbs)
- Insulin
- Granulocyte-Colony Stimulating Factor (G-CSF)
- Erythropoietin
- Human Growth Hormone (hGH)
- Interferons
- Others
Others Market Size & Forecast (2023-2030), By Application, USD Million
- Oncology
- Autoimmune Diseases
- Diabetes
- Blood Disorders
- Growth Hormone Deficiency
- Infectious Diseases
- Others
Market Size & Forecast (2023-2030), By Manufacturing Type, USD Million
- In-house Manufacturing
- Contract Manufacturing
Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the biosimilars market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the biosimilars market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
- Introduction
- Introduction
- Market Scope
- Market Definition
- Segments Covered
- Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2025-2026)
- Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Forecasting
- Executive Summary
- Biosimilars Market Snapshot (2025-2030)
- Segment Overview
- Regional Snapshot
- Competitive Insights
- Market Overview
- Market Dynamics
- Drivers
- Impending patent expiry of blockbuster biologics
- Cost containment strategies by governments and payers
- Rising demand for affordable alternatives for costly biologics
- Strong regulatory support and clear guidelines
- Increased physician and patient acceptance
- Restraints
- Complexity of manufacturing and development
- Pricing and reimbursement pressures
- Opportunities
- Emerging markets expansion
- Growing pipeline of biosimilars
- Growing adoption in oncology and chronic disease management
- Key Market Trends
- Strategic partnerships and market consolidation
- Advanced manufacturing technologies
- Unmet Market Needs
- Industry Speaks
- Drivers
- Market Dynamics
- Global Biosimilars Market Size & Forecast (2023-2030), By Product, USD Million
- Introduction
- Monoclonal Antibodies (mAbs)
- Insulin
- Granulocyte-Colony Stimulating Factor (G-CSF)
- Erythropoietin
- Human Growth Hormone (hGH)
- Interferons
- Others
- Global Biosimilars Market Size & Forecast (2023-2030), By Application, USD Million
- Introduction
- Oncology
- Autoimmune Diseases
- Diabetes
- Blood Disorders
- Growth Hormone Deficiency
- Infectious Diseases
- Others
- Global Biosimilars Market Size & Forecast (2023-2030), By Manufacturing Type, USD Million
- Introduction
- In-house Manufacturing
- Contract Manufacturing
- Global Biosimilars Market Size & Forecast (2023-2030), By Region, USD Million
- Introduction
- North America Biosimilars Market Size & Forecast (2023-2030), By Country, USD Million
- US
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Manufacturing Type (USD Million)
- Canada
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Manufacturing Type (USD Million)
- US
- Europe Biosimilars Market Size & Forecast (2023-2030), By Country, USD Million
- UK
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Manufacturing Type (USD Million)
- Germany
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Manufacturing Type (USD Million)
- France
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Manufacturing Type (USD Million)
- Italy
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Manufacturing Type (USD Million)
- Spain
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Manufacturing Type (USD Million)
- Rest of Europe
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Manufacturing Type (USD Million)
- UK
- Asia Pacific (APAC) Biosimilars Market Size & Forecast (2023-2030), By Country, USD Million
- China
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Manufacturing Type (USD Million)
- Japan
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Manufacturing Type (USD Million)
- India
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Manufacturing Type (USD Million)
- Rest of Asia Pacific
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Manufacturing Type (USD Million)
- China
- Latin America (LATAM) Biosimilars Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Manufacturing Type (USD Million)
- Middle East & Africa (MEA) Biosimilars Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Manufacturing Type (USD Million)
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2024)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2022-2025)
- New Product Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Company Profiles*
(Business Overview, Financial Performance**, Products Offered, Recent Developments)
- Sandoz Group AG
- Amgen Inc.
- Teva Pharmaceuticals, Inc.
- Biocon
- Eli Lilly and Company
- Celltrion Inc.
- Fresenius SE & Co. KGaA
- Samsung Bioepis
- Reddy’s Laboratories Ltd.
- Other Prominent Players
Note: *Indicative list
**For listed companies
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Stakeholders from Hospitals; Clinics; Research Institutes and Others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
